Determining whether the effect of liraglutide on non‐alcoholic fatty liver disease depends on reductions in the body mass index

Determining whether the effect of liraglutide on non‐alcoholic fatty liver disease depends on reductions in the body mass index

Abstract Background and Aim Non‐alcoholic fatty liver disease (NAFLD) initially presents as steatosis, which can progress to non‐alcoholic steatohepatitis (NASH), and often presents clinically alongside metabolic syndromes. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are regularly utilized...

Full description

Bibliographic Details
Main Authors: Megumi Shiomi, Yoichi Tanaka, Tesshu Takada, Katsuya Otori
Format: Article
Language:English
Published: Wiley 2020-10-01
Series:JGH Open
Subjects:
body mass index
liraglutide
non‐alcoholic fatty liver disease
type 2 diabetes mellitus
Online Access:https://doi.org/10.1002/jgh3.12384

Internet

https://doi.org/10.1002/jgh3.12384

Similar Items